Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm. According to GlobalData, Phase II drugs for Blepharospasm have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dipraglurant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dipraglurant overview

Dipraglurant is under development for the treatment of post-stroke recovery, traumatic brain injury (TBI), blepharospasm. The drug candidate is administered orally. It acts by targeting mGluR5. The drug candidate is developed based on allosteric modulator discovery technology platform. It is a negative allosteric modulator or NAM. It was under development for the treatment of dystonia, treatment resistant depression, addiction, anxiety disorders, Huntington disease, Lewy body dementia, obsessive-compulsive disorder, pain, levodopa induced dyskinesia associated with Parkinson's disease (PD-LID).

Addex Therapeutics overview

Addex Therapeutics (Addex) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson’s disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction, and mild neurocognitive and neurodegenerative disorders. The company has collaboration with Janssen Pharmaceuticals, Indivior PLC, government organizations and other academic researchers. Addex is headquartered in Geneva, Switzerland.

For a complete picture of Dipraglurant’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.